Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01704040
Recruitment Status : Completed
First Posted : October 11, 2012
Last Update Posted : December 12, 2014
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Tracking Information
First Submitted Date  ICMJE October 8, 2012
First Posted Date  ICMJE October 11, 2012
Last Update Posted Date December 12, 2014
Study Start Date  ICMJE October 2012
Actual Primary Completion Date November 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 10, 2012)
The maximum percent decrease relative to baseline in the prebronchodilator forced expiratory volume in 1 second (FEV1) measurements (Part 2) [ Time Frame: Up to 10 days after inoculation with human rhinovirus type 16 (HRV-16) ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 29, 2014)
  • Area under the serum concentration versus time curve (AUC) of change from baseline in Cold Symptom Assessment Score [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
    Cold symptoms is rated using a 5 point scale (0=none and 4=very severe). Scores can range from 0-32, with higher scores indicating more symptoms.
  • AUC of change from baseline in Cold and Chest Symptom Scale [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
    Cold and chest symptoms are rated using a 5 point scale: 0 using a 5 point scale (0=none and 4=very severe). Scores can range from 0-60, with higher scores indicating more symptoms.
  • AUC of change from baseline in log-transformed fractional concentration of exhaled nitric oxide (FENO) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the percent change from baseline in clinic assessed prebronchodilator FEV1 [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of change from baseline in morning (AM) peak expiratory flow rate (PEFR) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in prebronchodilator percent predicted FEV1 [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in prebronchodilator forced vital capacity (FVC) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in prebronchodilator forced expiratory flow at 25 to 75% of vital capacity (FEV25-75) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in prebronchodilator FEV1/FVC [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of change from baseline in average total asthma symptom diary score [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • Change from baseline in Asthma Control Questionnaire (ACQ) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
    ACQ is an instrument designed to evaluate asthma control. Seven items are scored on a 7-point scale (0=good control, 6=poor control) with the mean score as an overall summary score. Questions 1-6 are completed by the patient; the last item is entered by site personnel and corresponds to the patient's percent predicted FEV1 categorized according to the 7-point scale. Higher scores reflect poorer control.
  • Change from baseline in Cold Symptom Assessment Score [ Time Frame: Up to 11 weeks ]
    Clinical symptoms to HRV-16 will be assessed by using the Cold Symptom Assessment Score, wherein participants will report the presence and severity of their cold symptoms in the context of the previous 24 hours via an interactive interview with the study staff. The symptoms consist of nasal congestion (stuffy nose), rhinorrhea (runny nose), sore throat, sneezing, cough, headache, malaise (feeling run down, tired) and chilliness. Severity is rated using a 5 point scale (0=none, 1=mild, 2=moderate, 3=severe, and 4=very severe). Scores can range from 0-32, with higher scores indicating more symptoms.
  • Change from baseline in Cold and Chest Symptom Scale [ Time Frame: Up to 11 weeks ]
    The Cold and Chest Symptom Scale contains 15 items composing 2 domains, a total cold score and a total chest score. Together, these 2 domains comprise the chest symptom assessment score. Total Cold Score domain: sneezing, runny nose, blocked or stuff nose, sore throat or hoarse voice, headache or face pain, generally unwell, chills, fever or shivery and cough and Total Chest Score domain: cough on waking, wheeze on waking, daytime cough, daytime wheeze, daytime chest tightness, daytime breathlessness and nocturnal cough, wheeze and breathlessness. Severity is rated using a 5 point scale: 0 using a 5 point scale (0=none, 1=mild, 2=moderate, 3=severe, and 4=very severe). Scores can range from 0-60, with higher scores indicating more symptoms.
  • Change from baseline in log-transformed FENO over time [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in prebronchodilator and postbronchodilator FEV1 [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in percent-predicted prebronchodilator and postbronchodilator FEV1 [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in prebronchodilator and postbronchodilator FVC [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in prebronchodilator and postbronchodilator FEV25-75 [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in prebronchodilator and postbronchodilator FEV1/FVC [ Time Frame: Up to 11 weeks ]
  • Change from baseline in morning/evening PEFR over time [ Time Frame: Up to 11 weeks ]
  • Change from baseline in Total Nasal and Ocular Symptom Score (TNOSS) [ Time Frame: Up to Day 22 ]
    Nose and eye symptoms are rated by the patient using a 5-point categorical response scale from 0 to 4, where 0 indicates absent/no symptom, and 4 indicates extremely severe symptoms, with a 24-hour recall period.
  • Change from baseline in average total asthma symptom diary score [ Time Frame: Up to 11 weeks ]
  • Change from baseline in average number of nocturnal awakenings [ Time Frame: Up to 11 weeks ]
  • Change from baseline in average rescue medication use over time [ Time Frame: Up to 11 weeks ]
  • Number of symptom-free days [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • The maximum decrease from baseline in the prebronchodilator FEV1 measurements [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • Time to the maximum decrease relative to baseline in prebronchodilator FEV1 [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: October 10, 2012)
  • AUC of change from baseline in Cold Symptom Assessment Score [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
    Area under the serum concentration versus time curve (AUC) is a measure of blood serum concentration. Cold symptoms is rated using a 5 point scale (0=none and 4=very severe). Scores can range from 0-32, with higher scores indicating more symptoms.
  • AUC of change from baseline in Cold and Chest Symptom Scale [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
    Cold and chest symptoms are rated using a 5 point scale: 0 using a 5 point scale (0=none and 4=very severe). Scores can range from 0-60, with higher scores indicating more symptoms.
  • AUC of change from baseline in log-transformed fractional concentration of exhaled nitric oxide (FENO) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the percent change from baseline in clinic assessed prebronchodilator FEV1 [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of change from baseline in morning (AM) peak expiratory flow rate (PEFR) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in percent predicted FEV1 [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in forced vital capacity (FVC) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in forced expiratory flow at 25 to 75% of vital capacity (FEV25-75) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of the change from baseline in FEV1/FVC [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • AUC of change from baseline in average total asthma symptom diary score [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • Change from baseline in Asthma Control Questionnaire (ACQ) [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
    ACQ is an instrument designed to evaluate asthma control. Seven items are scored on a 7-point scale (0=good control, 6=poor control) with the mean score as an overall summary score. Questions 1-6 are completed by the patient; the last item is entered by site personnel and corresponds to the patient's percent predicted FEV1 categorized according to the 7-point scale. Higher scores reflect poorer control.
  • Change from baseline in Cold Symptom Assessment Score [ Time Frame: Up to 11 weeks ]
  • Change from baseline in Cold and Chest Symptom Scale [ Time Frame: Up to 11 weeks ]
  • Change from baseline in log-transformed FENO over time [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in FEV1 [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in percent-predicted FEV1 [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in FVC [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in FEV25-75 [ Time Frame: Up to 11 weeks ]
  • Change from baseline over time in FEV1/FVC [ Time Frame: Up to 11 weeks ]
  • Change from baseline in morning/evening PEFR over time [ Time Frame: Up to 11 weeks ]
  • Change from baseline in Total Nasal and Ocular Symptom Score (TNOSS) [ Time Frame: Up to Day 22 ]
    Nose and eye symptoms are rated by the patient using a 5-point categorical response scale from 0 to 4, where 0 indicates absent/no symptom, and 4 indicates extremely severe symptoms, with a 24-hour recall period.
  • Change from baseline in average total asthma symptom diary score [ Time Frame: Up to 11 weeks ]
  • Change from baseline in average number of nocturnal awakenings [ Time Frame: Up to 11 weeks ]
  • Change from baseline in average rescue medication use over time [ Time Frame: Up to 11 weeks ]
  • Number of symptom-free days [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • The maximum decrease from baseline in the prebronchodilator FEV1 measurements [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
  • Time to the maximum decrease relative to baseline in prebronchodilator FEV1 [ Time Frame: Up to 10 days after inoculation with HRV-16 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16
Official Title  ICMJE A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16
Brief Summary The main purposes of this study are to evaluate the safety (Parts 1 and 2) and efficacy (Part 2) of pretreatment with CNTO 3157 in healthy adult and asthmatic adult participants before and after intranasal (into the nose) inoculation with human rhinovirus type 16 (HRV-16).
Detailed Description This is a two-part, randomized (participants are assigned to treatment by chance), double-blind (participants and investigators do not know what study agent is being administered), placebo-controlled study. A placebo appears identical to a study agent, has no active ingredients, and helps investigators evaluate the effect of a study agent. In Part 1, following administration of CNTO 3157 or placebo, the severity of an upper respiratory tract infection, due to inoculation with HRV 16, will be assessed in healthy participants for safety reasons. In Part 2, following administration of CNTO 3157 or placebo and inoculation with HRV-16, efficacy and safety will be assessed in asthmatic participants using standard assessments to evaluate asthma treatments. The study (Parts 1 and 2) will be completed when the last participant completes the last visit (Week 11) in Part 2.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Condition  ICMJE Healthy Volunteers and Asthma
Intervention  ICMJE
  • Drug: CNTO 3157 (healthy participants)
    CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
  • Drug: Placebo (healthy participants)
    Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
  • Drug: CNTO 3157 (asthmatic patients)
    CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
  • Drug: Placebo (asthmatic patients)
    Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
  • Other: HRV-16
    Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
Study Arms  ICMJE
  • Experimental: Part 1: Healthy participants (CNTO 3157 + HRV-16)
    Interventions:
    • Drug: CNTO 3157 (healthy participants)
    • Other: HRV-16
  • Placebo Comparator: Part 1: Healthy participants (placebo + HRV-16)
    Interventions:
    • Drug: Placebo (healthy participants)
    • Other: HRV-16
  • Experimental: Part 2: Asthmatic patients (CNTO 3157 + HRV-16)
    Interventions:
    • Drug: CNTO 3157 (asthmatic patients)
    • Other: HRV-16
  • Placebo Comparator: Part 2: Asthmatic patients (placebo + HRV-16)
    Interventions:
    • Drug: Placebo (asthmatic patients)
    • Other: HRV-16
Publications * Silkoff PE, Flavin S, Gordon R, Loza MJ, Sterk PJ, Lutter R, Diamant Z, Turner RB, Lipworth BJ, Proud D, Singh D, Eich A, Backer V, Gern JE, Herzmann C, Halperin SA, Mensinga TT, Del Vecchio AM, Branigan P, San Mateo L, Baribaud F, Barnathan ES, Johnston SL. Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study. J Allergy Clin Immunol. 2018 Apr;141(4):1220-1230. doi: 10.1016/j.jaci.2017.06.027. Epub 2017 Jul 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 3, 2014)
76
Original Estimated Enrollment  ICMJE
 (submitted: October 10, 2012)
72
Actual Study Completion Date  ICMJE November 2014
Actual Primary Completion Date November 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Understanding of the study and a signed informed consent form before any study-related procedures
  • Willing and able to adhere to the restrictions specified in the protocol
  • Results of the following laboratory tests within the following limits: serum alanine aminotransferase (ALT) levels ≤2 x ULN; serum aspartate aminotransferase (AST) levels ≤2 x ULN
  • Part 1 (healthy participants):
  • a). Body weight in the range of 40 to 125 kg, inclusive. Have a body mass index (BMI) of 19 to 32 kg/m2, inclusive
  • b). Healthy with no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, hematologic assessments, coagulation and urinalysis, measurement of vital signs, and 12-lead electrocardiogram (ECG) performed at Screening Visit 2
  • Part 2:
  • a). (BMI) of 19 to 40 kg/m2, inclusive; have a physician-documented diagnosis of asthma for at least 6 months prior to Screening Visit 2; have stable asthma based on physician assessment at Screening Visit 2
  • b). Have an Asthma Control Questionnaire (ACQ) symptom score less than (<)2.5 at Screening Visit 2
  • c). Have a prebronchodilator forced expiratory volume in the first second (FEV1) greater than or equal to (>=) 65 percent of predicted normal value at Screening Visit 2

Exclusion Criteria:

  • Part 1 (healthy participants): Has any condition that in the opinion of the investigators, would constitute a risk or a contraindication for participating in the study, prevent the participant from meeting or performing study requirements, or could interfere with the study objectives, conduct, or evaluation
  • At Screening Visit 1 and throughout the study, works with (or lives with a family member who cares for) the elderly, (eg, nursing home), or lives with someone who may be at risk from transmission of the human rhinovirus type 16 (HRV-16) challenge agent, including, but not limited to, individuals with chronic lung disease (including asthma), a premature infant, or an immunocompromised individual
  • Has had any acute illness, including a common cold, within 4 weeks prior to Screening Visit 1, or has had a major illness or hospitalization within 6 months prior to Screening Visit 1
  • Has active allergic rhinitis or perennial allergy symptoms (eg, due to ragweed) at Screening Visit 2 or expects to have active allergic rhinitis or perennial allergy symptoms during the study
  • Has a current infection (eg, sepsis, pneumonia or pyelonephritis), or has been hospitalized and/or received antimicrobials for a serious infection during the 6 months prior to Screening Visit 1
  • Part 2 (asthmatic patients): Has a history of any other chronic lung disease, including chronic obstructive pulmonary disease (COPD), bronchiolitis, bronchiectasis, allergic bronchopulmonary aspergillosis (mycosis), occupational asthma, sleep apnea, pulmonary hypertension, or any other obstructive pulmonary disease, liver or renal insufficiency; significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, or other body system disorders that are clinically significant in the opinion of the investigator
  • Has ever had an episode of life-threatening asthma defined as respiratory arrest or requiring intubation for asthma
  • Has been hospitalized (for greater than 24 hours) due to asthma in the 5 years prior to Screening Visit 1
  • Has experienced an asthma exacerbation in the 12 weeks prior to Screening Visit 1 requiring management with systemic steroids
  • Is receiving a high-dose inhaled corticosteroid (ICS) (>500 µg/day to fluticasone or equivalent). Use of low or medium dose ICS (≤500 µg/day fluticasone or equivalent) with or without permitted controller medications, eg, long-acting Beta2 agonists (LABA), leukotriene receptor antagonists (LTRA), is allowed
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   Denmark,   Germany,   Netherlands,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01704040
Other Study ID Numbers  ICMJE CR100889
CNTO3157ASH1002 ( Other Identifier: Janssen Research & Development, LLC )
2011-005369-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Janssen Research & Development, LLC
Study Sponsor  ICMJE Janssen Research & Development, LLC
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
PRS Account Janssen Research & Development, LLC
Verification Date December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP